Heather Onorati is the Channel Content Director for Dermatology Times and Cosmetic Surgery Times.
The Food and Drug Administration has approved Nuvail (poly-ureaurethane 16 percent, Innocutis) nail solution for the treatment of nail dystrophy.
Washington - The Food and Drug Administration has approved Nuvail (poly-ureaurethane 16 percent, Innocutis) nail solution for the treatment of nail dystrophy.
Designed to treat brittle nail syndrome, Nuvail was formulated to mechanically support the damaged nail plate using a proprietary polymer blend that creates a strong adhesion to the nail surface, the company states. This forms a breathable barrier while protecting and strengthening the nail.
The breathable barrier allows for oxygen transfer to the nail plate while blocking water absorption, thus preventing the wet-dry cycle that leads to damaged nails. Daily application of Nuvail also protects the nail from harm caused by work activity such as direct abrasion and friction, according to the company.
"For the first time, patients will have a nail treatment that allows the nail to breathe but is still non-water-soluble and is able to protect the nail from the impact of moisture and friction," Jonathan Alba, Innocutis chief operating officer, said in a news release.
Nuvail is available in a 15-mL bottle.
Go back to the Dermatology Times eNews newsletter.